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ABSTRACT (Maximum 200 Words)
The cytotoxic T lymphocyte (CTL) has been considered the primary immune effector involved in mediating an anti-tumor response. Recent studies have demonstrated that "sensitization" of HER2 overexpressing tumor cells with trastuzumab, in vitro, will enhance the function of CTL specific for HER2. We have completed a Phase I study of a HER2 peptide based vaccine in women with HER2 overepxressing breast cancers without toxicity, particularly autoimmune or cardiac toxicity.
This proposal outlines a Phase II clinical trial designed to estimate survival in Stage IV HER2 positive breast cancer patients with no evidence of disease and receiving trastuzumab and a HER2 ICD peptide based vaccine.
In addition to survival we will assess the safety of combined immunotherapy, the immunogenicity of the approach, and whether the development of HER2 specific immunity correlates with clinical response. If we find that vaccinating against breast cancer after optimal treatment prevents or slow disease recurrence resulting in improved survival, more universal vaccine approaches can be rapidly developed and tested for the adjuvant treatment of all breast cancers. 
INTRODUCTION
The subject of this grant is to determine whether HER2 intracellular domain (ICD) peptide vaccine, administered in combination with trastuzumab, will enhance the effectiveness of this vaccine for treatment of patients with stage IV HER2-positive breast cancer.
The primary purpose of this grant is to determine the overall survival benefit in Stage IV HER2 positive breast cancer patients vaccinated with a HER2 ICD peptide-based vaccine while receiving maintenance trastuzumab.
The scope of the work includes a Phase II single arm study of a HER2 ICD peptide based vaccine given concurrently with trastuzumab. Patients enrolled will be HER2 over expressing stage IV breast cancer patients who have been treated to a clinical complete remission or have stable bone only disease and are within 6 months of starting maintenance trastuzumab. The primary objective is an estimate of overall survival (OS) compared to a historical control of patients treated with chemotherapy and trastuzumab (55% at 2 years). We hypothesize that the overall survival rate at 2 years with vaccination, if successful, would be 75%. 52 patients will provide 92% power to detect a statistically significant increased survival rate compared to the fixed historical rate of 55% at the one-sided significance level of .05. Secondary objectives are the assessment of the toxicity of the combined approach as well as the immunogenicity of HER2 ICD peptide vaccination. If there is evidence to suggest that the true rate of Grade IV toxicity exceeds 5% or the true rate of Grade III-IV toxicity exceeds 10% then the trial will be stopped for safety concerns. Immunogenicity of the approach will be evaluated as the ability of the vaccine to elicit HER2 ICD specific T cell immunity, to elicit epitope spreading, and to stimulate both a CD4+ and CD8+ immune response. Immune response and epitope spreading will then be modeled as time-dependent covariates in Cox proportional hazards regression models for OS to assess the correlation of each of these outcomes with the hazard of mortality.
BODY
Task 1: To assess the potential clinical impact of the administration of a HER2 ICD peptidebased vaccine to Stage IV breast cancer patients receiving concurrent trastuzumab monotherapy a. Reconstruct and vial the HER2 ICD peptide vaccine
The work plan has been delayed due to an initial delay in vaccine manufacture by our supplier. The peptides were produced by Multiple Peptide Systems (MPS), California under Good Manufacturing Practice (GMP) conditions. At the time the production was supposed to begin, MPS experienced a backlog of orders due to insufficient manufacturing space. For this reason, our manufacture was delayed 6 months. 
b. Enroll and treat patients
We have not enrolled any subjects into this study during the annual review period of April 27, 2004 to April 26, 2005 . Our accrual to this protocol began in May, 2005. This delay is due to the delay in reconstructing the peptide vaccine, as mentioned above.
As this is a Phase II study, the protocol is very specific in that that all subjects that enroll in this study must be enrolled within 6 months of initiating maintenance trastuzumab. We are consistently identifying potential subjects for this study, but by the time the vaccine was ready for administration many of them were no longer eligible to participate due to this eligibility inclusion criteria.
Currently we have 6 patients waiting to be scheduled to start the study. We have established collaboration with a large breast cancer practice in Southern California, "Breastlink" which refers patients to us specifically for immune based therapies. In addition, this study is a priority protocol within the breast cancer program at the UW/FHCRC. We plan an aggressive accrual to correct for the manufacturing delay.
c. Interim statistical analysis after 25 patients have been followed for I year
Not applicable for this reporting period. We understand that once we have enrolled 25 subjects that have been followed for 1 year we should perform an interim analysis of the data.
d. Final analysis of response
Not applicable during this reporting period.
Task 2: To evaluate the safety of administering a HER2 ICD peptide-based vaccine to Stage IV breast cancer patients receiving trastuzumab monotherapy a. Evaluate immediate toxicity associated with the vaccine
Not applicable to this reporting period. We will use the NCI Common Toxicity Criteria for Adverse Events Version 3.0 to grade toxicities. We will pay particular attention to local reactions associated with the injection site and systemic reactions to include but not limited to fever, malaise, myalgia, nausea and headache.
b. Determine whether there is any cardiac toxicity associated with the coadministration of the HER2 ICD peptide based vaccine with trastuzumab
Not applicable to this reporting period. We will document any abnormal cardiac events observed by us at clinic visits or reported to us by the subjects or physicians.
c. Evaluate for any potential toxicities due to the generation of an immune response to HER2
Not applicable to this reporting period. 
KEY RESEARCH ACCOMPLISHMENTS
Not applicable to this reporting period.
REPORTABLE OUTCOMES
CONCLUSIONS
The vaccine has been manufactured, vialed, and tested for quality assurance. The study has been approved by both the FDA and our Human Subjects Division and is currently enrolling patients.
